Edition:
United States

FibroGen Inc (FGEN.OQ)

FGEN.OQ on NASDAQ Stock Exchange Global Select Market

40.36USD
15 Nov 2018
Change (% chg)

-- (--)
Prev Close
$40.36
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
182,827
52-wk High
$68.15
52-wk Low
$38.52

Latest Key Developments (Source: Significant Developments)

Fibrogen Q3 Loss Per Share $0.50
Thursday, 8 Nov 2018 04:02pm EST 

FibroGen Inc ::FIBROGEN REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.50.Q3 EARNINGS PER SHARE VIEW $-0.35 -- THOMSON REUTERS I/B/E/S.PHASE 3 CLINICAL TRIALS IN IPF AND PANCREATIC CANCER TO INITIATE IN Q1 2019.QTRLY TOTAL REVENUE $29 MILLION VERSUS $40.6 MILLION.  Full Article

Fibrogen Q2 Loss Per Share $0.28
Tuesday, 7 Aug 2018 04:02pm EDT 

Aug 7 (Reuters) - FibroGen Inc ::FIBROGEN REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.28.Q2 EARNINGS PER SHARE VIEW $-0.59 -- THOMSON REUTERS I/B/E/S.QTRLY TOTAL REVENUE $43.95 MILLION VERSUS $30.27 MILLION.Q2 REVENUE VIEW $27.7 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

FibroGen Gets FDA Fast Track Designation For Its Pancreatic Cancer Treatment
Thursday, 1 Mar 2018 01:45pm EST 

March 1 (Reuters) - FibroGen Inc ::UPDATE - FIBROGEN GRANTED FAST TRACK DESIGNATION BY U.S. FDA FOR PAMREVLUMAB TREATMENT OF PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE PANCREATIC CANCER.FIBROGEN - FAST TRACK DESIGNATION FOLLOWS REVIEW OF CO'S PHASE 2 CLINICAL TRIAL EVALUATING PAMREVLUMAB IN COMBINATION WITH GEMCITABINE & NAB-PACLITAXEL.  Full Article

Fibrogen Granted Fast Track Designation By U.S. FDA For Pamrevlumab Treatment Of Patients
Thursday, 1 Mar 2018 07:00am EST 

March 1 (Reuters) - Fibrogen Inc ::FIBROGEN GRANTED FAST TRACK DESIGNATION BY U.S. FDA FOR PAMREVLUMAB TREATMENT OF PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE PANCREATIC CANCER.  Full Article

FibroGen Q4 Loss Per Share $0.27
Tuesday, 27 Feb 2018 04:10pm EST 

Feb 27 (Reuters) - Fibrogen Inc ::FIBROGEN REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.27.QTRLY ‍TOTAL REVENUE OF $42.5 MILLION VERSUS $31.9 MILLION.  Full Article

Fibrogen Inc reports Q3 loss per share $0.50
Wednesday, 8 Nov 2017 04:02pm EST 

Nov 8 (Reuters) - Fibrogen Inc ::Fibrogen reports third quarter 2017 financial results.Q3 loss per share $0.50.Q3 earnings per share view $-0.37 -- Thomson Reuters I/B/E/S.nda filing for roxadustat for anemia in​ ckd with u.s. Food and drug administration targeted for 2018.qtrly ‍total revenue $27.3 million versus $30.1 million.  Full Article

Fibrogen announces acceptance by china FDA of roxadustat NDA for treatment of anemia associated with dialysis and non-dialysis kidney disease
Wednesday, 18 Oct 2017 07:00am EDT 

Oct 18 (Reuters) - Fibrogen Inc :Fibrogen announces acceptance by china FDA of roxadustat new drug application (NDA) for treatment of anemia associated with dialysis and non-dialysis chronic kidney disease (CKD).Fibrogen - ‍under terms of Fibrogen's agreement with Astrazeneca, NDA submission triggers a $15 million milestone payment, payable to co by Astrazeneca​.  Full Article

Fibrogen announces pricing of follow-on offering of common stock
Tuesday, 15 Aug 2017 11:31pm EDT 

Aug 15 (Reuters) - Fibrogen Inc - :Fibrogen, Inc. announces pricing of follow-on offering of common stock.Fibrogen Inc - offering 8 million shares of its common stock at an offering price of $40.75 per share, before underwriting discounts and commissions.  Full Article

FibroGen announces proposed follow-on offering of common stock
Monday, 14 Aug 2017 04:26pm EDT 

Aug 14 (Reuters) - Fibrogen Inc :Fibrogen Inc announces proposed follow-on offering of common stock.Fibrogen Inc - ‍intends to offer and sell up to $300 million of its common stock in an underwritten follow-on offering​.Fibrogen Inc - anticipates using net proceeds to fund expansion of product development, manufacturing and commercialization activities​.  Full Article

Fibrogen ‍net loss per diluted share for quarter ended June 30 was $0.48
Monday, 7 Aug 2017 05:47pm EDT 

Aug 7 (Reuters) - Fibrogen Inc :Fibrogen Inc - ‍net loss per basic and diluted share for quarter ended June 30, 2017 was $0.48 - SEC filing​.Fibrogen Inc - ‍at June 30, 2017, Fibrogen had $414.7 million of cash, restricted time deposits, cash equivalents, investments, and receivables​.Q2 earnings per share view $-0.47 -- Thomson Reuters I/B/E/S.Fibrogen Inc - ‍company announces positive topline results from Phase 2 study in IPF​.Fibrogen- ‍pamrevlumab continued to be well tolerated as monotherapy in IPF study, was well tolerated in combination with pirfenidone and nintedanib​.Fibrogen inc - ‍believe that promising outcomes of the studies enable us to advance pamrevlumab into Phase 3 clinical development​.  Full Article

Boost for 'made in China' medicine as Chi-Med wins key approval

LONDON Hutchison China MediTech has won Chinese approval for a closely watched new cancer drug in a significant boost for "made in China" medicine.